{"id":"beacoppesc-abvd-pet2","safety":{"commonSideEffects":[{"rate":null,"effect":"Myelosuppression (neutropenia, thrombocytopenia)"},{"rate":null,"effect":"Nausea and vomiting"},{"rate":null,"effect":"Alopecia"},{"rate":null,"effect":"Mucositis"},{"rate":null,"effect":"Cardiotoxicity (doxorubicin-related)"},{"rate":null,"effect":"Pulmonary toxicity (bleomycin-related)"},{"rate":null,"effect":"Peripheral neuropathy (vincristine-related)"},{"rate":null,"effect":"Infertility risk"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"This is a combined chemotherapy approach for Hodgkin lymphoma that alternates or combines bleomycin, etoposide, doxorubicin, cyclophosphamide, vincristine, procarbazine, and prednisone (BEACOPP escalated) with doxorubicin, bleomycin, vinblastine, and dacarbazine (ABVD). PET imaging after 2 cycles (PET2) is used as a prognostic tool to identify early responders versus non-responders, allowing treatment intensification or modification based on metabolic response rather than fixed protocols.","oneSentence":"BEACOPPesc-ABVD-PET2 is a chemotherapy regimen combined with PET imaging to guide treatment intensity in Hodgkin lymphoma, using escalated BEACOPP and ABVD chemotherapy with PET-2 response assessment to tailor subsequent therapy.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T01:03:54.068Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Hodgkin lymphoma, early-stage and advanced-stage (treatment guided by PET-2 response)"}]},"trialDetails":[{"nctId":"NCT01358747","phase":"PHASE3","title":"Study of a Treatment Driven by Early PET Response to a Treatment Not Monitored by Early PET in Patients With AA Stage 3-4 or 2B HL","status":"COMPLETED","sponsor":"Centre Hospitalier Universitaire Dijon","startDate":"2011-05","conditions":"Hodgkin's Lymphoma","enrollment":""}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"BEACOPPesc - ABVD - PET2","genericName":"BEACOPPesc - ABVD - PET2","companyName":"Centre Hospitalier Universitaire Dijon","companyId":"centre-hospitalier-universitaire-dijon","modality":"Small molecule","firstApprovalDate":"","aiSummary":"BEACOPPesc-ABVD-PET2 is a chemotherapy regimen combined with PET imaging to guide treatment intensity in Hodgkin lymphoma, using escalated BEACOPP and ABVD chemotherapy with PET-2 response assessment to tailor subsequent therapy. Used for Hodgkin lymphoma, early-stage and advanced-stage (treatment guided by PET-2 response).","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}